PA8845601A1 - Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) - Google Patents
Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)Info
- Publication number
- PA8845601A1 PA8845601A1 PA20098845601A PA8845601A PA8845601A1 PA 8845601 A1 PA8845601 A1 PA 8845601A1 PA 20098845601 A PA20098845601 A PA 20098845601A PA 8845601 A PA8845601 A PA 8845601A PA 8845601 A1 PA8845601 A1 PA 8845601A1
- Authority
- PA
- Panama
- Prior art keywords
- trpv1
- vanilloid
- receiver antagonists
- potential transitory
- transitory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
COMPUESTOS DE FÓRMULA (I) O SALES, SOLVATOS, PRODROGAS O SALES DE PRODROGAS FARMACÉUTICAMENTE ACEPTABLES DE ÉSTOS, O SUS COMBINACIONES DONDE R1, R2, R3, R4 Y M TIENEN LOS VALORES QUE SE DEFINEN EN LA MEMORIA DESCRIPTIVA. COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS Y MÉTODOS PARA TRATAR AFECCIONES Y TRASTORNOS USANDO DICHOS COMPUESTOS Y DICHAS COMPOSICIONES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10636908P | 2008-10-17 | 2008-10-17 | |
US22007509P | 2009-06-24 | 2009-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8845601A1 true PA8845601A1 (es) | 2010-05-26 |
Family
ID=41571121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20098845601A PA8845601A1 (es) | 2008-10-17 | 2009-10-15 | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) |
Country Status (11)
Country | Link |
---|---|
US (1) | US8604053B2 (es) |
EP (1) | EP2352726A1 (es) |
JP (1) | JP2012505907A (es) |
CN (1) | CN102186836A (es) |
AR (1) | AR073631A1 (es) |
CA (1) | CA2737768A1 (es) |
MX (1) | MX2011004081A (es) |
PA (1) | PA8845601A1 (es) |
TW (1) | TW201020236A (es) |
UY (1) | UY32180A (es) |
WO (1) | WO2010045401A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045402A1 (en) * | 2008-10-17 | 2010-04-22 | Abbott Laboratories | Trpv1 antagonists |
US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
CN103635458B (zh) * | 2011-03-25 | 2016-10-19 | 艾伯维公司 | Trpv1拮抗剂 |
WO2013096223A1 (en) | 2011-12-19 | 2013-06-27 | Abbvie Inc. | Trpv1 antagonists |
US8969325B2 (en) | 2011-12-19 | 2015-03-03 | Abbvie Inc. | TRPV1 antagonists |
US9567302B2 (en) | 2012-03-19 | 2017-02-14 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
JP6115303B2 (ja) * | 2012-05-18 | 2017-04-19 | Jnc株式会社 | 隣接基としてカルボニル基を有するフェノール化合物およびその用途 |
US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
US9981972B2 (en) | 2014-05-22 | 2018-05-29 | Abide Therapeutics, Inc. | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets |
US10336709B2 (en) | 2015-10-02 | 2019-07-02 | Abide Therapeutics, Inc | Lp-PLA2 inhibitors |
KR20240010527A (ko) * | 2017-07-06 | 2024-01-23 | 디그니티 헬쓰 | 안면 홍조를 위한 신규 치료법 |
CN108929270B (zh) * | 2018-08-15 | 2021-06-08 | 上海罕道医药科技有限公司 | 一种药物中间体双取代含氮杂环的胺类化合物的合成 |
JP2022523916A (ja) | 2019-01-30 | 2022-04-27 | モンテリノ・セラピューティクス・インコーポレイテッド | アンドロゲン受容体を標的とするユビキチン化のための二官能性化合物および方法 |
JP6830569B1 (ja) | 2019-08-23 | 2021-02-17 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
ES2214546T3 (es) | 1995-09-15 | 2004-09-16 | PHARMACIA & UPJOHN COMPANY | N-oxidos de aminoariloxazolidinona. |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
KR101150324B1 (ko) * | 2003-06-12 | 2012-06-13 | 아보트 러보러터리즈 | 바닐로이드 수용체 아형 1(vr1) 수용체를 억제하는 융합 화합물 |
US7651514B2 (en) * | 2003-12-11 | 2010-01-26 | Boston Scientific Scimed, Inc. | Nose rider improvement for filter exchange and methods of use |
EP1737850B1 (en) | 2004-04-19 | 2007-10-03 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
US7429661B2 (en) | 2004-07-20 | 2008-09-30 | Symed Labs Limited | Intermediates for linezolid and related compounds |
US7511013B2 (en) * | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
CA2588909A1 (en) * | 2004-11-24 | 2006-06-22 | Abbott Laboratories | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) * | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
US7842703B2 (en) * | 2005-10-07 | 2010-11-30 | Glenmark Pharmaceuticals S.A. | Substituted benzofused derivatives and their use as vanilloid receptor ligands |
RU2008121205A (ru) | 2005-10-28 | 2009-12-10 | Абботт Лаборэтриз (Us) | Производные индазола (варианты), включающая их фармацевтическая композиция и способ лечения или предупреждения заболеваний, чувствительных к ингибированию рецептора trpv1 (варианты) |
MY144307A (en) * | 2006-04-18 | 2011-08-29 | Abbott Lab | Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof |
KR20090064435A (ko) | 2006-10-04 | 2009-06-18 | 뉴로키 에이/에스 | 허혈의 치료를 위한 저체온 유도제의 사용 |
EP2083807A2 (en) | 2006-10-04 | 2009-08-05 | Neurokey A/S | Use of a combination of hypothermia inducing drugs |
US8796267B2 (en) * | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008059339A2 (en) | 2006-11-13 | 2008-05-22 | Glenmark Pharmaceuticals S.A. | Isoquinoline derivatives as vanilloid receptor modulators |
EP2134678A2 (en) * | 2006-12-20 | 2009-12-23 | Abbott Laboratories | N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain |
WO2008098857A1 (en) * | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
WO2008110863A1 (en) | 2007-03-15 | 2008-09-18 | Glenmark Pharmaceuticals S.A. | Indazole derivatives and their use as vanilloid receptor ligands |
KR20100012031A (ko) * | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
US7531685B2 (en) * | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) * | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) * | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
JP2010540635A (ja) * | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
US20090105338A1 (en) * | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
WO2009051782A1 (en) * | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
CL2008003092A1 (es) * | 2007-10-19 | 2009-11-27 | Abbott Gmbh & Co Kg | Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende . |
CA2703591C (en) * | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
WO2010045402A1 (en) * | 2008-10-17 | 2010-04-22 | Abbott Laboratories | Trpv1 antagonists |
-
2009
- 2009-10-15 AR ARP090103975A patent/AR073631A1/es not_active Application Discontinuation
- 2009-10-15 UY UY0001032180A patent/UY32180A/es not_active Application Discontinuation
- 2009-10-15 MX MX2011004081A patent/MX2011004081A/es not_active Application Discontinuation
- 2009-10-15 JP JP2011532227A patent/JP2012505907A/ja active Pending
- 2009-10-15 CA CA2737768A patent/CA2737768A1/en not_active Abandoned
- 2009-10-15 PA PA20098845601A patent/PA8845601A1/es unknown
- 2009-10-15 CN CN2009801412472A patent/CN102186836A/zh active Pending
- 2009-10-15 WO PCT/US2009/060732 patent/WO2010045401A1/en active Application Filing
- 2009-10-15 TW TW098134972A patent/TW201020236A/zh unknown
- 2009-10-15 US US12/579,821 patent/US8604053B2/en active Active
- 2009-10-15 EP EP09740591A patent/EP2352726A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AR073631A1 (es) | 2010-11-17 |
US20100137360A1 (en) | 2010-06-03 |
CA2737768A1 (en) | 2010-04-22 |
JP2012505907A (ja) | 2012-03-08 |
US8604053B2 (en) | 2013-12-10 |
EP2352726A1 (en) | 2011-08-10 |
TW201020236A (en) | 2010-06-01 |
UY32180A (es) | 2010-05-31 |
CN102186836A (zh) | 2011-09-14 |
MX2011004081A (es) | 2011-05-31 |
WO2010045401A1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
EA201991123A1 (ru) | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
SV2006002098A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a | |
UY28765A1 (es) | Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
ECSP078018A (es) | Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento | |
CR10314A (es) | Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina | |
UY35275A (es) | Derivados de aminopirazina | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
CY1121898T1 (el) | Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4 | |
UY32520A (es) | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides | |
EA201190086A1 (ru) | Сочлененные производные имидазола в качестве антагониста trpv3 | |
CO6531479A2 (es) | Derivados de espirolactama y uso de los mismos | |
UY29733A1 (es) | Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotrópicos | |
SV2011003839A (es) | Agentes antifungicos |